Evidence map›Paper›PMID 41266617›Full record

ArticleEMBO reports2026

FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer.

Suzan Ber, Ming Yang, Marco Sciacovelli, Shamith Samarajiwa, Khushali Patel, Efterpi Nikitopoulou, Annie Howitt, Simon J Cook, Ashok R Venkitaraman, Christian Frezza and 1 more

Abstract read
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Suzan BerMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.ORCID 0000-0003-4219-6032
Ming YangMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Marco SciacovelliMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Shamith SamarajiwaMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Khushali PatelMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Efterpi NikitopoulouMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Annie HowittMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.
Simon J CookSignalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK.
Ashok R VenkitaramanMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.ORCID 0000-0002-6876-2672
Christian FrezzaMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK.ORCID 0000-0002-3293-7397
Alessandro EspositoMRC Cancer Unit, University of Cambridge, Cambridge, CB2 0XZ, UK. alessandro.esposito@brunel.ac.uk.ORCID 0000-0002-5051-091X

Funding

Alexander von Humboldt-Stiftung (AvH) n/acambridgeuniversity | Cancer Research UK Cambridge Institute, University of Cambridge (CRUK CI) C9685/A25117,C9685/A28397Cancer Research UK (CRUK) C51061/A27453Cancer Research UK (CRUK) C54674/A27487EC | ERC | HORIZON EUROPE European Research Council (ERC) ERC819920EC | Horizon 2020 Framework Programme (H2020) 101073507EC | Horizon 2020 Framework Programme (H2020) 101135034 (UKRI #10107542)UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) BB/J004456/1,BB/P013384/1 and BB/Y006925/1UKRI | Medical Research Council (MRC) MC_UU_12022/1 and MC_UU_12022/8UKRI | Medical Research Council (MRC) MRC_MC_UU_12022/6
6 · The paper itself

Abstract

Mutations in KRAS, particularly at codon 12, are frequent in adenocarcinomas of the colon, lungs and pancreas, driving carcinogenesis by altering cell signalling and reprogramming metabolism. However, the specific mechanisms by which different KRAS G12 alleles initiate distinctive patterns of metabolic reprogramming are unclear. Using isogenic panels of colorectal cell lines harbouring the G12A, G12C, G12D and G12V heterozygous mutations and employing transcriptomics, metabolomics, and extensive biochemical validation, we characterise distinctive features of each allele. We demonstrate that cells harbouring the common G12D and G12V oncogenic mutations significantly alter glutamine metabolism and nitrogen recycling through FOXO1-mediated regulation compared to parental lines. Moreover, with a combination of small molecule inhibitors targeting glutamine and glutamate metabolism, we also identify a common vulnerability that eliminates mutant cells selectively. These results highlight a previously unreported mutant-specific effect of KRAS alleles on metabolism and signalling that could be potentially harnessed for cancer therapy.

Indexed as

Colorectal NeoplasmsForkhead Box Protein O1GlutamineNitrogenProto-Oncogene Proteins p21(ras)AllelesCell Line, TumorGene Expression Regulation, NeoplasticHumansMutationSignal TransductionForkhead Box Protein O1FOXO1 protein, humanGlutamineKRAS protein, humanNitrogenProto-Oncogene Proteins p21(ras)Colorectal CancerFOXO SignallingGlutamine MetabolismGlutamine SynthaseKRAS Mutation

Identifiers

PMID41266617
PMCPMC12795846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.